ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

CUE Cue Biopharma Inc

1.35
0.01 (0.75%)
19 Jun 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Cue Biopharma Inc NASDAQ:CUE NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.01 0.75% 1.35 1.35 4.20 1.42 1.26 1.33 335,971 05:00:05

Cue Biopharma to Present at the Jefferies 2023 Global Healthcare Conference

05/06/2023 1:00pm

GlobeNewswire Inc.


Cue Biopharma (NASDAQ:CUE)
Historical Stock Chart


From Jun 2022 to Jun 2024

Click Here for more Cue Biopharma Charts.

Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modulate disease-specific T cells directly within the patient’s body, announced today that it will present at the Jefferies Global Healthcare Conference being held June 7–9, 2023 in New York.

The Company will provide a corporate update highlighting the most recent clinical progress for CUE-101, its lead clinical asset from the interleukin 2 (IL-2)-based CUE-100 series, being evaluated as monotherapy and in combination with pembrolizumab (KEYTRUDA®) for the treatment of patients with recurrent/metastatic HPV16+ head and neck cancer. The presentation will also provide an update on the second clinical drug candidate from the IL-2-based CUE-100 series, CUE-102, for patients with Wilms’ Tumor 1 (WT1)-positive cancers, as well as CUE-401, a bispecific protein designed to induce and expand regulatory T cells (Tregs) for the treatment of autoimmune and inflammatory diseases.

Presentation DetailsJefferies 2023 Global Healthcare Conference Date and Time: Friday, June 9 at 12:15 p.m. EDT Webcast Link: https://wsw.com/webcast/jeff281/cue/1688830

A live and archived webcast of the presentation will be available in the Investor and Media section of the Company’s website at www.cuebiopharma.com. The webcast will be archived for 30 days.

About the CUE-100 Series  The CUE-100 series consists of Fc-fusion biologics that incorporate peptide-MHC (pMHC) molecules along with rationally engineered IL-2 molecules. This singular biologic is anticipated to selectively target, activate and expand a robust repertoire of tumor-specific T cells directly in the patient’s body. The binding affinity of IL-2 for its receptor has been deliberately attenuated to achieve preferential selective activation of tumor-specific effector T cells while reducing the potential for effects on regulatory T cells (Tregs) or broad systemic activation, potentially mitigating the dose-limiting toxicities associated with current IL-2-based therapies.

About Cue BiopharmaCue Biopharma, a clinical-stage biopharmaceutical company, is developing a novel class of injectable biologics to selectively engage and modulate disease-specific T cells directly within the patient’s body. The company’s proprietary platform, Immuno-STAT™ (Selective Targeting and Alteration of T cells) and biologics are designed to harness the body’s intrinsic immune system as T cell engagers without the need for ex vivo manipulation or broad systemic modulation.

Headquartered in Boston, Massachusetts, we are led by an experienced management team and independent Board of Directors with deep expertise in immunology and immuno-oncology as well as the design and clinical development of protein biologics.

For more information please visit www.cuebiopharma.com and follow us on Twitter at https://twitter.com/CueBiopharma.

Investor ContactMarie CampinellSenior Director, Corporate CommunicationsCue Biopharma, Inc.mcampinell@cuebio.com

Media ContactMaya RomanchukLifeSci Communicationsmromanchuk@lifescicomms.com

1 Year Cue Biopharma Chart

1 Year Cue Biopharma Chart

1 Month Cue Biopharma Chart

1 Month Cue Biopharma Chart

Your Recent History

Delayed Upgrade Clock